• Journal of Digestive Cancer Research
• /
• v.10 no.2
• /
• pp.49-55
• /
• 2022

Helicobacter pylori (H. pylori) infection is associated with gastroduodenal diseases such as gastritis, peptic ulcer diseases, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. Furthermore, various extragastroduodenal diseases have been suggested to be related with H. pylori infection. Although no single factor has been considered the cause of gastroesophageal reflux disease (GERD), a negative association was found between the prevalence of H. pylori and GERD severity. Additionally, the role of eradication therapy of H. pylori in reflux esophagitis is controversial, and a significant correlation was found between successful H. pylori eradication rate and reflux esophagitis development. H. pylori infection remains an inconclusive and important issue in GERD. Thus, more experimental studies are necessary to elucidate the potential mechanisms.

• Journal of Life Science
• /
• v.17 no.7 s.87
• /
• pp.1002-1018
• /
• 2007

Ever since the World Health Organization classified Helicobacter pylori as a class I carcinogen, a variety of discussions over the actual role of H. pylori infection in gastric carcinogenesis has existed. Although a majority of researches support the positive correlation between H. pylori infection and the development of gastric cancer, many aspects of this association are yet uncertain, and some data even suggest that there may be no correlation between H. pylori infection and gastric carcinogenesis. However, there are proofs indicating these reports underestimated the prevalence of H. pylori infection and therefore, the association of the infection and gastric adenocarcinoma. In this report, I reviewed the epidemiology of H. pylori and gastric cancer, evidence supporting and against the positive correlation of the infection and the disease, and the possible pathological role H. pylori infection may have in gastric carcinogenesis referring particular to published literature. As a conclusion, despite a few reports of a possible negative or no relationship between gastric cancer and H. pylori infection, I was able to find that H. pylori infection did have a pathological role in the development of gastric cancer.

• The Korean journal of helicobacter and upper gastrointestinal research
• /
• v.18 no.3
• /
• pp.147-149
• /
• 2018

• BMB Reports
• /
• v.31 no.3
• /
• pp.240-244
• /
• 1998

Helicobacter pylori is the etiologic agent of human gastritis and peptic ulceration and produces urease as the major protein component on its surface. H. pylori urease is known to serve as a major virulence factor and in a potent immunogen. In order to express the recombinant urease at a higher level, a DNA fragment containing the minimal H. pylori urease gene cluster was subcloned into a high copy-number vector. The recombinant H. pylori urease expressed in an E. coli strain that was grown in a rich medium supplemented with added nickel was purified to near homogeneity by using DEAE-Sepharose, Superdex HR200, and Mono-Q (FPLC) columns and the purified enzyme possessed the specific activity of 1255 U/mg. Polyclonal antibodies raised against the purified recombinant H. pylori urease were shown to be very specific when subjected to Western blot analysis, in which crude extracts from the H. pylori ATCC strain and the recombinant E. coli strains expressing various bacterial ureases were exnmined for cross-reactivity.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1996.04a
• /
• pp.197-197
• /
• 1996

Helicobacter pylori (H. pylori) is a microaerophilic spiral bacterium and infection by it in the human stomach causes gastritis, furthermore, it is considered to be involved in the pathogenesis of peptic ulcers and the development of gastric carcinoma. We assessed the inhibitory activity of new antiulcer drugs against Helicobacter pylori. The activities of new antiulcer agents against Helicobacter pylori strains were determined by the standard agar dilution method with blood agar base #2, supplemented with 5% sheep blood and 4 antibiotics to support growth of these organisms. They were inoculated by multipoint inoculator and incubated at 37$^{\circ}C$ for 3 days under microaerophilic atmosphere. The MIC of antiulcer agents was the lowest concentration that inhibited visible growth of these organisms. According to results of various biochemical tests, these bacteria were identified as Helicobacter pylori strains. And the MIC results showed that the strains were very susceptible to omeprazole and YJA20379s. Some of YJA20379s were more potent than omeprazole. These results suggest that our new antiulcer drugs have potent inhibitory activity against Helicobacter pylori, so that our new antiulcer drugs might be useful for the clinical eradication of gastrointestinal Helicobacter pylori.

• Korean Journal of Pharmacognosy
• /
• v.35 no.4 s.139
• /
• pp.350-356
• /
• 2004

In a preliminary screening of plant extracts for the antigastritic and anti- Helicobacter pylori (H. pylori) actions in rats, the ethanol extract of Amomi Semen (AS) showed positive activity in HCl Ethanol-induced gastric lesions and H. pylori. Among the systematic fractions of hexane, chloroform, butanol and water, the most potent butanol fraction significantly reduced HCl, Ethanol-induced gastric lesions at the oral dose of 350 mg/kg. Also butanol fraction has an inhibitory effect on the growth of H. pylori $(MIC=1.43\;{\mu}g/mL)$. In pylorus ligated rats, butanol fraction showed decrease in the volume of gastric secretion and acid output, of which effects were stronger in other fractions. We isolated 6 subfractions by column chromatography. The protective effects of 6 subfractions of Amomi Semen were also significant in the HCl, Ethanol induced gastric lesion model. These results might suggest that they had inhibitory action in gastric lesion through inhibition of gastric acid secretion. Butanol fraction of AS can be applied as treatment of H. pylori. Butano fractions and ethanol extract of AS was carried out or the development of a new gastroprotective supplementary product.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.1 no.1
• /
• pp.9-18
• /
• 1998

• Safe Food
• /
• v.1 no.3
• /
• pp.44-52
• /
• 2006

• The Journal of the Korean life insurance medical association
• /
• v.19
• /
• pp.69-73
• /
• 2000

• The Journal of the Korean life insurance medical association
• /
• v.19
• /
• pp.9-14
• /
• 2000